All Resources

Access to Medicine • August 21, 2023

IMC Response to the PMPRB’s 2023 Interim Guidance Consultation

Learn more | View

Access to Medicine • August 21, 2023

pCPA Temporary Access Process: Innovative Medicines Industry Consultation Response

Learn more | View

Pharmacare • June 01, 2023

Addendum to Innovative Medicines Canada Submission on National Pharmacare

Learn more | View

Access to Medicine • May 16, 2023

Developing a Canadian managed entry approach for new innovation: What can Canada learn from Europe?

Learn more | View

May 04, 2023

Submission to Health Canada regarding the Draft guidance on advanced therapeutic products framework

Learn more | View

Access to Medicine • May 02, 2023

Clinical Trials in Canada

Learn more | View

Access to Medicine • February 15, 2023

Alberta Budget Submission 2023

Learn more | View

Patented Medicine Prices Review Board (PMPRB) • December 05, 2022

The Suspension and Reformulation of the PMPRB Guidelines is Urgently Required: IMC Response to PMPRB 2022 Guidelines Proposals

Learn more | View

Access to Medicine • November 17, 2022

Innovative Agreements Framework

…describes innovative agreements being used in jurisdictions outside Canada. We prepared it to guide discussions with the pCPA Governing Council on the merits of jointly developing an innovative agreements framework….

Learn more | View

Access to Medicine • July 06, 2022

Developing a Pan-Canadian Genomics Strategy: Innovative Medicines Canada Response

Learn more | View

Access to Medicine • February 12, 2022

Optimizing Patient Access to Precision Therapies: Preparing for the Emerging Era of Advanced Testing

Learn more | View

Access to Medicine • February 05, 2022

Bluesky Project

Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022…

Learn more | View